Abstract
Objectives: To examine the effects of anti-psychotic medications on cardiovascular parameters in overdose. Specifically, to examine dose–response relationships for thioridazine and chlorpromazine. Methods: A retrospective study of case records of patients presenting to the Edinburgh poisons treatment unit over 3 years (2000–2002). Information—including that on stated dose ingested, ECG parameters, and pulse and blood pressure—was extracted from case notes. Results: A total of 224 chlorpromazine, 96 thioridazine and 99 patients ingesting other anti-psychotics were evaluated. Full data on all aspects, both dose and cardiovascular change, was available in 96 chlorpromazine, 36 thioridazine and 27 of the other anti-psychotic cases. For thioridazine, there was a significant dose–response relationship for increasing heart rate and increasing QTc but not other cardiovascular changes. For chlorpromazine, there was no dose–response relationship for ECG changes, but there was a significant dose–response relationship for increasing heart rate and reduction in mean blood pressure. Conclusions: We have confirmed a relationship between increasing dose of thioridazine and prolongation of QTc in overdose patients. No such change was observed with chlorpromazine. Both of these agents are reported to cause QT prolongation, but this study suggests that the nature of these effects is different for each agent. Poisoned patients may offer ways of exploring in more detail, and at a larger dose range, the effects of potentially cardiotoxic drugs in humans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Roden DM (2004) Drug induced prolongation of the QT interval. N Engl J Med 350:1013–1022
Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048–1052
Haddad PM, Anderson IM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:1649–1671
Taylor DM (2003) Antipsychotics and QT prolongation. Acta Psychiatr Scand 107:85–95
Bateman DN, Good AM, Afshari R, Kelly CA (2003) Effects of licence change on prescribing and poisons enquires for antipsychotic agents in England and Scotland. Br J Clin Pharmacol 55:596–693
Davies SJC, Cooke LB, Moore AG, Potokar J (2002) Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. Br Med J 324:1519–1521
Czekalla J, Kollack-Walker S, Beasley CM (2001) Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 62(suppl2):35–40
Hulisz DT, Dasa SL, Black LD, Heiselman DE (1994) Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 14:239–245
Gury C, Canceil O, Iaria P (2000) Antipsychotic drugs and cardiovascular safety: current study of prolonged QT interval and risk of ventricular arrhythmia. Encephale 26:62–72
Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ (1997) Gender and the relationship between ventricular repolarisation and the cardiac cycle length during 24-h Holter recordings. Eur Heart J 18:1000–1006
De Ponti F, Poluzzi E, Montanaro N (2000) Qt-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56:1–18
Bril A, Gout B, Bonhomme M, Landais L, Faivre J, Linee P, Poyser RH, Ruffolo RR (1996) Combined potassium and calcium channel blocking activities as a basis for arythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 276:637–646
Goodnick PJ, Parra F, Jerry J (2002) Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 3:479–498
MCA/CSM (2001) QTc prolongation with antipsychotics. Curr Probl 27:4
Warner JP, Barnes TR, Henry JA, (1996) Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93:311–313
Good AM, Strachan F, Oliver J, Kelly CA, Bateman DN (2002) Licensing decisions and TOXBASE®—evaluating the effect of restricted indications for thioridazine on its use in acute overdose. J Clin Pharmacol 53:416–417
Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J (1999) Thioridazine lengthens repolarisation of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288:1261–1268
Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB (1976) Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 37:223–230
Hartington-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL (1996) Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 60:543–553
Hale P, Poklis A (1996) Thioridazine cardiotoxicity. Clin Toxicol 34:127–128
Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL (2002) Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 180:515–522
Buckley NA, Whyte IM, Dawson AH (1995) Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33:199–204
Mortensen PB, Juel K (1993) Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163:183–189
Belardinelli L, Antzelevitch C, Vos MA (2003) Assessing predictors of drug induced torsade de pointes. TIPS 24:619–625
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Strachan, E.M., Kelly, C.A. & Bateman, D.N. Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning. Eur J Clin Pharmacol 60, 541–545 (2004). https://doi.org/10.1007/s00228-004-0811-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-004-0811-7